In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...
Investor's Business Daily on MSN3d
Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rallied.Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
Roivant Sciences Ltd. (NASDAQ:ROIV), a pharmaceutical company with a market capitalization of $7.8 billion and a "GOOD" financial health rating according to InvestingPro, disclosed on Thursday ...
Bank of New York Mellon Corp raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 17.4% during the fourth quarter, according to the company in its most recent 13F filing with the ...
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...
Roivant Sciences Ltd. has a 52-week low of $9.80 and a 52-week high of $13.06. Roivant Sciences ( NASDAQ:ROIV – Get Free Report ) last posted its quarterly earnings results on Monday, February 10th.
Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...
In its fourth quarter 2024 investor letter, Tourlite Capital Management emphasized stocks such as Roivant Sciences Ltd. (NASDAQ:ROIV). Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback